M1611 Epigenetic Characterization of a Novel Tumor Suppressor Gene, RNF180, in Gastric Cancer and Its Application in Noninvasive Cancer Detection

Kin-Fai Cheung,Cleo N. Y. Lam,Wai K. Leung,Alfred S. L. Cheng,Enders K. Ng,Wai-Sing Chong,Hongchuan Jin,Joseph J. Y. Sung,Jun Yu
DOI: https://doi.org/10.1016/s0016-5085(08)61781-3
IF: 29.4
2008-01-01
Gastroenterology
Abstract:stomach and esophagus.Quantitative real-time RT-PCR (qRT-PCR) and immunohistochemical (IHC) staining on tumor tissue microarrays (TMA) were used to study the expression of AURKA.To investigate the biological and signaling impact of AURKA, we utilized multiple In Vitro assays that included MTT, TUNEL, cytochrome C release, flow cytometry, luciferase reporter, and Western blots analysis.We detected frequent over-expression of AURKA transcript in UGCs as compared to normal samples (47%, P=.001).The IHC analysis of 130 tumors demonstrated moderate-to-strong immunostaining of AURKA in more than 50% of UGCs.Using camptothecin, as a drug-induced apoptosis In Vitro model, we demonstrated that the expression of AURKA provided protection against apoptosis to gastrointestinal cancer cells (AGS and RKO) (P=.006) and RIE-1 primary intestinal epithelial cells (P=.001).The AURKA over-expression mediated an increase in phosphorylation of AKTSer473 with an increase in HDM2 level.The shRNA-knockdown of AKT in AURKA over-expressing cells reversed this effect and showed a significant increase in the p53 protein level, indicating a possible nexus of AURKA/AKT/p53.Indeed, over-expression of AURKA led to a remarkable reduction in the transcription activity of p53, with subsequent reductions in transcript and protein levels of its downstream pro-apoptotic transcription targets (p21, BAX, NOXA, and PUMA).Our results indicate that AURKA provides potent anti-apoptotic properties to gastrointestinal cells by regulating the levels of p53 through the AKT/HDM2 axis.
What problem does this paper attempt to address?